5-HT2A receptor
11 drugs CNS
4
approved indications
11
Approved Drugs
9
Companies
9
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (9 companies)
✓ All 11 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (9 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
AbbVie 2 drugs
ALKERMES INC 2 drugs
XIAMEN LP PHARM CO 1 drug
By Therapeutic Area
CNS 10 drugs
Other 1 drugs
Drugs by Company PRO
ALKERMES INC 2 drugs
XIAMEN LP PHARM CO 1 drug
UNICHEM 1 drug
OTSUKA PHARM CO LTD 1 drug
DOUGLAS PHARMS 1 drug
OTSUKA 1 drug
HISAMITSU 1 drug
Teva 1 drug
By Therapeutic Area
CNS 10 drugs
OPIPZA, ARIPIPRAZOLE, SAPHRIS, ABILIFY MAINTENA KIT +6 more
Other 1 drugs
CLOZAPINE
Indications Treated
SchizophreniaAutistic DisorderTourette’s DisorderMajor Depressive DisorderAutismTourette SyndromeBipolar I DisorderManiaSchizoaffective Disorder
All Drugs Targeting 5-HT2A receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| OPIPZA | XIAMEN LP PHARM CO | 2024 | 4 | CNS |
| ARIPIPRAZOLE | UNICHEM | 2015 | 3 | CNS |
| SAPHRIS | AbbVie | 2009 | 3 | CNS |
| ABILIFY MAINTENA KIT | OTSUKA PHARM CO LTD | 2013 | 3 | CNS |
| VRAYLAR | AbbVie | 2015 | 2 | CNS |
| VERSACLOZ | DOUGLAS PHARMS | 2013 | 2 | CNS |
| ABILIFY ASIMTUFII | OTSUKA | 2023 | 2 | CNS |
| ARISTADA INITIO KIT | ALKERMES INC | 2018 | 1 | CNS |
| SECUADO | HISAMITSU | 2019 | 1 | CNS |
| ARISTADA | ALKERMES INC | 2015 | 1 | CNS |
| CLOZAPINE | Teva | 1996 | - |